These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32208600)

  • 1. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Soga K; Honjo T; Takai S; Kawano Y; Kikuchi M; Nishidate A; Matsumoto F; Murase M; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129849. PubMed ID: 38876177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Dimethylisoxazole-Attached Imidazo[1,2-
    Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
    J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
    McDaniel KF; Wang L; Soltwedel T; Fidanze SD; Hasvold LA; Liu D; Mantei RA; Pratt JK; Sheppard GS; Bui MH; Faivre EJ; Huang X; Li L; Lin X; Wang R; Warder SE; Wilcox D; Albert DH; Magoc TJ; Rajaraman G; Park CH; Hutchins CW; Shen JJ; Edalji RP; Sun CC; Martin R; Gao W; Wong S; Fang G; Elmore SW; Shen Y; Kati WM
    J Med Chem; 2017 Oct; 60(20):8369-8384. PubMed ID: 28949521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins.
    Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Comput Biol Chem; 2021 Dec; 95():107592. PubMed ID: 34710811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
    Wang L; Pratt JK; Soltwedel T; Sheppard GS; Fidanze SD; Liu D; Hasvold LA; Mantei RA; Holms JH; McClellan WJ; Wendt MD; Wada C; Frey R; Hansen TM; Hubbard R; Park CH; Li L; Magoc TJ; Albert DH; Lin X; Warder SE; Kovar P; Huang X; Wilcox D; Wang R; Rajaraman G; Petros AM; Hutchins CW; Panchal SC; Sun C; Elmore SW; Shen Y; Kati WM; McDaniel KF
    J Med Chem; 2017 May; 60(9):3828-3850. PubMed ID: 28368119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives.
    Akawa OB; Soremekun OS; Olotu FA; Solima MES
    Curr Pharm Biotechnol; 2022; 23(3):444-456. PubMed ID: 33749556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
    Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
    Wu X; Shi Z; Hsu DK; Chong J; Huynh M; Mendoza L; Yamada D; Hwang ST
    J Dermatol Sci; 2020 Oct; 100(1):31-38. PubMed ID: 32900573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.